Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Emyria Ltd ( (AU:EMD) ) just unveiled an announcement.
Emyria says its first Empax clinic in Victoria remains on schedule to begin treating patients in the second quarter of 2026, marking a key step in its national rollout of reimbursable mental health services. The clinic will expand the company’s treatment footprint and capacity while supporting the broader scaling of the Empax model.
To de-risk execution, the company has contracted and trained 31 Victorian therapists and six psychiatrists, secured medication supply, and finalised a site agreement with Avive Health to start fit-out and governance integration. Revenue visibility is bolstered by dual reimbursement pathways from Medibank Private and the Department of Veterans’ Affairs, reducing reliance on self-funded patients and underpinning early utilisation rates.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
More about Emyria Ltd
Emyria Ltd is an ASX-listed healthcare company focused on developing and delivering innovative, evidence-based mental health treatments. Through its Empax clinic model, the company targets conditions such as treatment-resistant depression and post-traumatic stress disorder, with a strategy to expand a reimbursable national clinic network in partnership with hospitals and payers.
Average Trading Volume: 1,362,452
Technical Sentiment Signal: Sell
Current Market Cap: A$32.26M
Find detailed analytics on EMD stock on TipRanks’ Stock Analysis page.